Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obesity 2016: Minimally Invasive Bariatric Devices Gaining Steam

Executive Summary

With no end in sight for the obesity epidemic, there is a vast and underserved market opportunity for manufacturers developing minimally invasive solutions for obesity that can fill the treatment gap between invasive bariatric surgery and conservative weight loss methods (diet, exercise, and drugs). Despite some high-profile setbacks in the last few years, the market for minimally invasive bariatric devices is gaining steam as several companies have recently launched obesity devices on the US market while others have completed clinical trials and are advancing toward US regulatory approval.

You may also be interested in...



Market Intel: Intragastric Balloons And Other Innovations To Inflate Weight Loss Devices Market

The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.

CMS Advisors Say More Evidence Needed For Obesity Surgery

Bariatric surgery may offer good results for younger patients, but CMS advisors felt the evidence wasn’t there to guarantee successful results for older patients on Medicare.

US FDA Warns of Deaths Tied To Gastric Balloons

The agency doesn’t yet know the exact causes of the five deaths. This is the second safety alert on the obesity-treatment devices this year.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT103608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel